Treatment of elderly patients with type 2 diabetes mellitus: A systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors

Cheung, 2009, Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006, Am J Med, 122, 443, 10.1016/j.amjmed.2008.09.047 Centers for Disease Control and Prevention. National diabetes fact sheet: General information and national estimates on diabetes in the United States, 2005. Atlanta, Ga: US Department of Health and Human Services, Centers for Disease Control and Prevention, 2005. Narayan, 2006, Impact of recent increase in incidence on future diabetes burden: US, 2005-2050, Diabetes Care, 29, 2114, 10.2337/dc06-1136 2008 2010, Standards of medical care in diabetes—2010 [published correction appears in Diabetes Care. 2010;33:692], Diabetes Care, 33, S11 McDonald, 2009, Prevalence, awareness, and management of hypertension, dyslipidemia, and diabetes among United States adults aged 65 and older, J Gerontol A Biol Sci Med Sci, 64, 256, 10.1093/gerona/gln016 Vik, 2004, Measurement, correlates, and health outcomes of medication adherence among seniors, Ann Pharmacother, 38, 303, 10.1345/aph.1D252 Nied, 2002, Promoting and prescribing exercise for the elderly, Am Fare Physician, 65, 419 Hornick, 2008, Managing diabetes in the elderly: Go easy, individualize, Cleve Clin J Med, 75, 70, 10.3949/ccjm.75.1.70 Brown, 2003, Guidelines for improving the care of the older person with diabetes mellitus, J Am Geriatr Soc, 51, S265 Bolen, 2007, Systematic review: Comparative effectiveness and safety of oral medications for type 2 diabetes mellitus [published correction appears in Ann Intern Med. 2007;147:887], Ann Intern Med, 147, 386, 10.7326/0003-4819-147-6-200709180-00178 Gerich, 2005, PRESERVE-beta: Two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin, Diabetes Care, 28, 2093, 10.2337/diacare.28.9.2093 Hartman, 2008, Insulin analogs: Impact on treatment success, satisfaction, quality of life, and adherence, Clin Med Res, 6, 54, 10.3121/cmr.2008.793 Yang, 2008, The financial burden of overweight and obesity among elderly Americans: The dynamics of weight, longevity, and health care cost, Health Serv Res, 43, 849, 10.1111/j.1475-6773.2007.00801.x Poirier, 2006, Obesity and cardiovascular disease: Pathophysiology, evaluation, and effect of weight loss, Arterioscler Thromb Vase Biol, 26, 968, 10.1161/01.ATV.0000216787.85457.f3 Daousi, 2006, Prevalence of obesity in type 2 diabetes in secondary care: Association with cardiovascular risk factors, Postgrad Med J, 82, 280, 10.1136/pmj.2005.039032 Fisman, 2009, A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease, Cardiovasc Diabetol, 8, 38, 10.1186/1475-2840-8-38 Brown, 2003, Guidelines for improving the care of the older person with diabetes mellitus, J Am Geriatr Soc, 51, S265, 10.1046/j.1532-5415.51.5s.1.x Schnabel, 2006, Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes, Vase Health Risk Manag, 2, 69, 10.2147/vhrm.2006.2.1.69 Nathan, 2009, Medical management of hypergly cemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes, Diabetes Care, 32, 193, 10.2337/dc08-9025 Nicolucci, 2008, Incretin-based therapies: A new potential treatment approach to overcome clinical inertia in type 2 diabetes, Acta Biomed, 79, 184 Raz, 2008, Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes, Curr Med Res Opin, 24, 537, 10.1185/030079908X260925 Barzilai, 2009, Sitagliptin is well tolerated and leads to rapid improvement in blood glucose in the first days of monotherapy in patients aged 65 years and older with T2DM, Diabetes, 58, 587-P Maheux, 2009, Efficacy and safety of saxagliptin 5 mg once-daily therapy in elderly patients with type 2 diabetes mellitus, Diabetologia, 52, S302 Pratley, 2007, Management of type 2 diabetes in treatment-naive elderly patients: Benefits and risks of vildagliptin monotherapy, Diabetes Care, 30, 3017, 10.2337/dc07-1188 Fonseca, 2007, Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes, Diabetologia, 50, 1148, 10.1007/s00125-007-0633-0 Garber, 2008, Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea, Diabetes Obes Metab, 10, 1047, 10.1111/j.1463-1326.2008.00859.x Ferrannini, 2009, Fifty-two-week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately con trolled on metformin monotherapy [published correction appears in Diabetes Obes Metab. 2009;11:405], Diabetes Obes Metab, 11, 157, 10.1111/j.1463-1326.2008.00994.x Fonseca, 2008, Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus, Horm Metab Res, 40, 427, 10.1055/s-2008-1058090 Goodman, 2009, Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy, Horm Metab Res, 41, 368, 10.1055/s-0028-1104604 Scherbaum, 2008, Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycaemia, Diabetes Obes Metab, 10, 675, 10.1111/j.1463-1326.2008.00850.x Pratley, 2009, Alogliptin use in the elderly: A pooled analysis from phase 2-3 studies, Diabetes, 58, 462-P Pratley, 2009, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy, Diabetes Obes Metab, 11, 167, 10.1111/j.1463-1326.2008.01016.x Van Gaal, 2008, Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: Glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?, Eur J Endocrinol, 158, 773, 10.1530/EJE-07-0804 Chacra, 2009, Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: A randomised controlled trial, Int J Clin Pract, 63, 1395, 10.1111/j.1742-1241.2009.02143.x Rosenstock, 2009, Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes, Curr Med Res Opin, 25, 2401, 10.1185/03007990903178735 Jadzinsky, 2009, Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: A randomized controlled trial, Diabetes Obes Metab, 11, 611, 10.1111/j.1463-1326.2009.01056.x Hollander, 2009, Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabe tes and inadequate control on thiazolidinedione alone, J Clin Endocrinol Metab, 94, 4810, 10.1210/jc.2009-0550 Ebell, 2004, Strength of recommendation taxonomy (SORT): A patient-centered approach to grading evidence in the medical literature, Am Fare Physician, 69, 548 Goldstein, 2007, Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 in hibitor, and metformin on glycemic control in patients with type 2 diabetes [published correction appears in Diabetes Care. 2008;31:1713], Diabetes Care, 30, 1979, 10.2337/dc07-0627 Aschner, 2006, Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes, Diabetes Care, 29, 2632, 10.2337/dc06-0703 Raz, 2006, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in pa tients with type 2 diabetes mellitus, Diabetologia, 49, 2564, 10.1007/s00125-006-0416-z Rosenstock, 2006, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongo ing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study, Clin Ther, 28, 1556, 10.1016/j.clinthera.2006.10.007 Nonaka, 2008, Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes, Diabetes Res Clin Pract, 79, 291, 10.1016/j.diabres.2007.08.021 Mohan, 2009, Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea, Diabetes Res Clin Pract, 83, 106, 10.1016/j.diabres.2008.10.009 Scott, 2008, Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes, Diabetes Obes Metab, 10, 959, 10.1111/j.1463-1326.2007.00839.x Hermansen, 2007, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin, Diabetes Obes Metab, 9, 733, 10.1111/j.1463-1326.2007.00744.x Nauck, 2009, Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A multicentre, randomised, double-blind, placebo-controlled study, Int J Clin Pract, 63, 46, 10.1111/j.1742-1241.2008.01933.x 2009 2009 Rodbard, 2009, Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: An algorithm for glycemic control [published correction appears in Endocr Pract. 2009;15:768-770], Endocr Pract, 15, 540, 10.4158/EP.15.6.540 Meece, 2006, Dispelling myths and removing barriers about insulin in type 2 diabetes, Diabetes Educ, 32, 9S, 10.1177/0145721705285638 Greco, 2004, Drug-induced severe hypoglycaemia in type 2 diabetic patients aged 80 years or older, Diabetes Nutr Metab, 17, 23 Whitmer, 2009, Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus, JAMA, 301, 1565, 10.1001/jama.2009.460 Skyler, 2009, Circulation, 119, 351, 10.1161/CIRCULATIONAHA.108.191305 Bremer, 2009, Hypoglycemia unawareness in older compared with middleaged patients with type 2 diabetes, Diabetes Care, 32, 1513, 10.2337/dc09-0114 Lassmann-Vague, 2005, Hypoglycaemia in elderly diabetic patients, Diabetes Metab, 31 Neumiller, 2009, Pharmacological management of glycemic control in the geriatric patient with type 2 diabetes mellitus, Consult Pharm, 24, 45, 10.4140/TCP.n.2009.45 American Academy of Family Physicians, American Diabetes Association. The benefits and risks of controlling blood glucose levels in patients with type 2 diabetes mellitus. A re view of the evidence and recommendations. Aldhahi, 2004, Beta-cell insulin secretory response to oral hypoglycemic agents is blunted in humans in vivo during moderate hypoglycemia, J Clin Endocrinol Metab, 89, 4553, 10.1210/jc.2004-0266 Suh, 2008, Comorbid conditions and glycemic control in elderly patients with type 2 diabetes mellitus, 1988 to 1994 to 1999 to 2004, J Am Geriatr Soc, 56, 484, 10.1111/j.1532-5415.2007.01563.x White, 2009, Efficacy and safety of incretin-based therapies: Clinical trial data, J Am Pharm Assoc (2008), 49, S30, 10.1331/JAPhA.2009.09079 Wolf, 2009, Evaluation of CV risk in saxagliptin clinical trials, Diabetes (2003), 58, 8-LB University of British Columbia; Merck Frosst Canada Ltd. Sitagliptin in the elderly. In: ClinicalTrials.gov [Internet]. Bethesd, Md: National Library of Medicine (US); AstraZeneca; Bristol-Myers Squibb. Saxagliptin compared to glimepiride in elderly type 2 diabetes patients, with inadequate glycemic control on metformin (GENERATION). In: ClinicalTrials.gov [Internet]. Bethesda, Md: National Library of Medicine (US); Takeda Global Research & Development Center, Inc. Efficacy and safety of alogliptin compared to glipizide in elderly diabetics. In: ClinicalTrials.gov [Internet]. Bethesda, Md: National Library of Medicine (US); Boehringer Ingelheim Pharmaceuticals. Efficacy and safety of linagliptin in elderly patients with type 2 diabetes. In: ClinicalTrials.gov [Internet]. Bethesd, Md: Na tional Library of Medicine (US);